Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
Pharmalot
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

A bill would slow the revolving door between pharma and federal agencies

  • Ed Silverman

By Ed Silverman Nov. 2, 2017

Reprints
FDA; Drug Administration campus
Andrew Harnik/AP

Should there be a doorstop in the revolving door between drug makers and regulatory agencies?

Several U.S. senators believe so, and on Thursday they introduced legislation  that would take two steps to slow the pace at which individuals move between the pharmaceutical industry and both the Food and Drug Administration and the Drug Enforcement Administration.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed Silverman covers the pharmaceutical industry.

Tags

3 keys to successful biopharma-academia drug development collaborations
3 keys to successful biopharma-academia drug development collaborations
Fentanyl test strips could help save lives. In many…
Fentanyl test strips could help save lives. In many states, they’re still illegal
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Biden administration goes easy on Medicare Advantage insurers after…
Biden administration goes easy on Medicare Advantage insurers after intense industry lobbying
European Union drug pricing proposal for the pandemic treaty…
European Union drug pricing proposal for the pandemic treaty generates pushback
Inflation caused a sizable drop in net drug prices…
Inflation caused a sizable drop in net drug prices in late 2022, analysis finds

Recommended Stories